Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide e.g. large cell lymphoma or restenosis are treated with a thioredoxin reductase inhibitor e.g. auranofin or arsenic trioxide and a nitric oxide donating compound e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity e.g. Parkinson's disease or se...

Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient in need thereof by administering a therapeutically effective amount of one or more of these compounds alone or in combination with another drug therapy. The compounds and pharmaceutical compositions disclosed are useful to treat proliferative diseases and disorder...

Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient in need thereof by administering a therapeutically effective amount of one or more of these compounds, alone or in combination with another drug therapy. The compounds and pharmaceutical compositions disclosed are useful to treat proliferative diseases and disorde...

Disclosed herein are methods for treating obesity, metabolic syndrome, diabetes, or a combination of these conditions. The methods include selecting a subject with obesity, metabolic syndrome, or diabetes and administering to the subject a therapeutically effective amount of a composition comprising a compound that specifically inhibits hepatic protein kinase C (PKC)-[tau], thereby treating the obesity, metabolic syndrome, or diabetes in the subject. In some embodiments the compound that specifi...

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide e.g. large cell lymphoma or restenosis are treated with a thioredoxin reductase inhibitor e.g. auranofin or arsenic trioxide and a nitric oxide donating compound e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity e.g. Parkinson's disease or se...

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide e.g. large cell lymphoma or restenosis are treated with a thioredoxin reductase inhibitor e.g. auranofin or arsenic trioxide and a nitric oxide donating compound e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity e.g. Parkinson's disease or se...

The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate gold compounds antimalarials cyclosporine A leflunomide azathioprine sulfasalazine d-penicillamine aurothioglucose auranofin or a TNF inhibitor.

Uso de i) una sustancia fisiológicamente activa seleccionada del grupo que consiste en un analgésico un agente antiinflamatorio un DMARD un inhibidor de la degradación de cartílago un inmunomodulador un inmunosupresor un agente antialérgico un inhibidor de resorción ósea y un antioxidante y ii) un polímero biocompatible que permite una liberación sostenida de la sustancia fisiológicamente activa para la preparación de una nanocápsula para administración intra-articular para el trata...

The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate gold compounds antimalarials cyclosporine A leflunomide azathioprine sulfasalazine d-penicillamine aurothioglucose auranofin or a TNF inhibitor.